Evaluation of 24-hour intragastric pH using esomeprazole, lansoprazole, and pantoprazole in Hispanic patients with GERD
Study identifier:D9612L00106
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomized, Open-Label, Comparative 3-Way Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40 mg, Lansoprazole 30 mg, and Pantoprazole 40 mg at Steady State in Hispanic Patients with Symptomatic GERD
Medical condition
Gastroesophageal Reflux Disease
Phase
Phase 4
Healthy volunteers
No
Study drug
Esomeprazole 40mg, Pantoprazole 40mg, Lansoprazole 30mg
Sex
All
Actual Enrollment
90
Study type
Interventional
Age
18 Years - 69 Years
Date
Study Start Date: 01 Oct 2006
Primary Completion Date: -
Study Completion Date: 01 May 2007
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Marta Illueca
AstraZeneca
